DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Apremilast
Drug: Placebo
Other: Topical or Phototherapy Therapy

First Posted Date: 2010-11-02

Last Posted Date: 2022-03-15

Lead Sponsor: Amgen

Target Recruit Count: 413

Registration Number: NCT01232283

Locations: 🇺🇸
Clinical Science Institute, Santa Monica, California, United States
🇺🇸
Northwestern University Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸
Radiant Research, Inc., Anderson, South Carolina, United States

and more 42 locations

The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam

Phase 1

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Midazolam
Drug: Denosumab

First Posted Date: 2010-10-15

Last Posted Date: 2018-08-07

Lead Sponsor: Amgen

Target Recruit Count: 30

Registration Number: NCT01221727

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo + 20 mg Apremilast
Drug: Apremilast 30mg
Drug: Apremilast 20mg
Drug: Placebo + 30 mg Apremilast

First Posted Date: 2010-10-01

Last Posted Date: 2020-05-06

Lead Sponsor: Amgen

Target Recruit Count: 488

Registration Number: NCT01212757

Locations: 🇧🇪
CHU Brugmann, Bruxelles, Belgium
🇧🇬
Diagnostic and Consulting Centre 4, Varna, Bulgaria
🇪🇪
East Tallinn Central Hospital, Tallinn, Estonia

and more 93 locations

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: AMG 386 Placebo
Drug: AMG 386
Drug: Paclitaxel

First Posted Date: 2010-09-17

Last Posted Date: 2016-12-15

Lead Sponsor: Amgen

Target Recruit Count: 919

Registration Number: NCT01204749

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: AMG 827

First Posted Date: 2010-09-10

Last Posted Date: 2021-11-26

Lead Sponsor: Amgen

Target Recruit Count: 315

Registration Number: NCT01199289

Locations: 🇷🇺
Research Site, Saint Petersburg, Russian Federation

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Phase 3

Completed

Conditions: Cystinosis

Interventions: Drug: Cysteamine Bitartrate Delayed-release Capsules

First Posted Date: 2010-09-09

Last Posted Date: 2024-12-27

Lead Sponsor: Amgen

Target Recruit Count: 60

Registration Number: NCT01197378

Locations: 🇺🇸
Stanford University Medical School, Stanford, California, United States
🇫🇷
Robert Debre Hospital, Paris, France
🇺🇸
Texas Children's Hospital/Baylor University, Houston, Texas, United States

and more 7 locations

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Apremilast
Drug: Placebo
Drug: Topical treatments or phototherapy

First Posted Date: 2010-09-02

Last Posted Date: 2022-03-15

Lead Sponsor: Amgen

Target Recruit Count: 844

Registration Number: NCT01194219

Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis

Phase 4

Completed

Conditions: Hyperparathyroidism, Secondary

Interventions: Drug: Traditional Vitamin D Therapy
Drug: Cinacalcet

First Posted Date: 2010-08-13

Last Posted Date: 2018-10-17

Lead Sponsor: Amgen

Target Recruit Count: 312

Registration Number: NCT01181531

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Aeroquin
Drug: Placebo

First Posted Date: 2010-08-12

Last Posted Date: 2024-12-18

Lead Sponsor: Amgen

Target Recruit Count: 330

Registration Number: NCT01180634

Locations: 🇦🇺
Westmead Chilren's Hospital, Westmead, New South Wales, Australia
🇺🇸
Childrens Hospital, Los Angeles, California, United States
🇦🇺
Mater Miscericordiae Hospital, Brisbane, Queensland, Australia

and more 11 locations

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Apremilast 20mg
Drug: Placebo + 30 mg Apremilast
Drug: Apremilast 30mg
Drug: Placebo + 20 mg Apremilast

First Posted Date: 2010-07-30

Last Posted Date: 2020-06-19

Lead Sponsor: Amgen

Target Recruit Count: 504

Registration Number: NCT01172938

Locations: 🇺🇸
Physicians East, Greenville, North Carolina, United States
🇳🇿
Timaru Hospital, Timaru, New Zealand
🇪🇸
Hospital Universitario Marques de Valdecilla, Santander, Spain

and more 88 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy